Publications & Insights

Show
In
Published

Medicaid and Long-Term Care: New Challenges, New Opportunities, and Implications for a Comprehensive National Long-Term Care Strategy

June 2010

Prepared for: Genworth Financial
Lewin contact: Lisa Alecxih

A number of factors will likely result in dramatic changes to the financing and delivery of long-term care (LTC) services—an increasing population of older people and people with disabilities, a severe economic recession, the new national health reform law, and other recent developments. This study, conducted by The Lewin Group for Genworth Financial, synthesizes the latest available data on Medicaid and LTC trends; takes a new look at LTC financing challenges and possible solutions in light of these historic changes; and proposes guidelines for consideration in developing a comprehensive, national long-term care solution.

Client Area: Payers / Insurers
Expertise Area: Aging and Disability

Patient Protection and Affordable Care Act (PPACA): Long Term Costs for Governments, Employers, Families and Providers

June 2010

Lewin Contact: John Sheils

In this study we provide estimates of the cost and coverage impacts of the Patient Protection and Affordable Care Act (PPACA). We estimate the program’s impact on sources of health insurance coverage and spending for the federal government, state and local governments, private employers, consumers and providers. We estimated the impact of the Act over a 10 year period from 2010 through 2019, which is consistent with the “budget window” used by the Congressional Budget Office (CBO). However, we also provide estimates for 2020 through 2029.

We developed these estimates using the Group Health Benefits Simulation Model (HBSM) developed by the Lewin Group. Our revenue and spending estimates over the 20-year period reflect the actual phase in of coverage provisions and expected lags in enrollment for newly eligible people. However, to illustrate the program’s impact on sources of coverage and family spending, we present estimates assuming that Act is fully implemented and that enrollment has fully matured in 2011.

Expertise Area: Health Reform

State Economic Impact of the Medical Technology Industry

June 2010

Prepared for: Advamed
Lewin Contact: Cliff Goodman

This report presents updated estimates of the medical technology industry’s (MTI) economic contributions from the previous industry analysis, which was released in 2007. The industry encompasses the manufacturing of everyday medical devices, such as contact lenses and thermometers, to high-tech equipment, such as implantable pacemakers, neurostimulators and state-of-the-art imaging systems. Each of the 50 States and the District of Columbia are benefitted by MTI establishments; nearly all have seen this industry grow since the 2007 report.

Client Area: Associations, Pharma / Bio / Device

Projected Economic Impact of Eliminating California’s Medi-Cal Adult Day Health Care Program

May 2010

Prepared for the Congress of California Seniors
Lewin Contact: Lisa Alecxih

This study estimates the potential State revenue impacts associated with the proposed elimination of the Medi-Cal ADHC program. While the proposed elimination of the Medi-Cal ADHC program would save direct expenses on the program, policymakers should also consider the potential negative impacts of the elimination on cost-shifting to other more expensive care settings, loss of jobs among ADHC employees, reductions in family caregivers’ ability to work, loss of State tax revenue, forfeiting $164 million annually in federal Medicaid matching funds and economic impact on local businesses and other entities that would lose revenue from the elimination of adult day health care providers.

Client Area: Foundations, State and Local Governments
Expertise Area: Aging and Disability

Will Health Reform Slow Cost Growth?

March 2010

Lewin Contact: John Sheils

Expertise Area: Health Reform

Narrative Matters ‘How Much Does Zozo Weigh Today?’

March 2010

Lewin Contact: Anjali Jain

Expertise Area: Chronic Disease / Cost of Illness

Temptations In Cyberspace: New Battlefields In Childhood Obesity

March 2010

Lewin Contact: Anjali Jain

Expertise Area: Chronic Disease / Cost of Illness

Individuals Living in the Community with Chronic Conditions and Functional Limitations : A Closer Look

February 2010

DHHS, Office of the Assistant Secretary for Planning and Evaluation (ASPE)
Lewin contact: Lisa Alecxih

On January 28, the Engelberg Center for Health Care Reform at Brookings hosted a forum to discuss strategies for improving care for older Americans across a range of institutional and community-based settings. Experts and key stakeholders examined the components of health care reform most likely to influence older Americans; discussed promising models for payment, delivery-system reforms, and coordination across a continuum of care; and identified how quality and efficiency can be improved.

During the forum, Richard Frank, Deputy Assistant Secretary for Office of Disability, Aging, and Long-Term Care Policy for the Assistant Secretary for Planning and Evaluation, officially released a chartbook prepared by The Lewin Group. The chartbook takes a closer look at the health spending for individuals with chronic conditions and functional impairments living in the community. The Lewin Group analysis indicates that the combination of chronic conditions and functional limitations is a critical indicator and an improved targeting criteria for individuals with high health spending who could benefit from better coordination and management.

Client Area: Federal Government
Expertise Area: Aging and Disability

Comparing the House and Senate Health Reform Bills: Long Term Costs for Governments, Employers, Families and Providers

February 2010

Lewin contact: John Sheils

The purpose of this analysis was to compare the effects of two major proposals to reform the U.S. health care system. These include the Senate “Patient Protection and Affordable Care Act” and the “Affordable Health Care for America Act” passed by the House of Representatives. This study provides estimates of the programs' impact on coverage and spending for the federal government, state and local governments, private employers, consumers and providers. We estimated the impact of both bills on federal spending over a 20 year period from 2010 through 2029. The Congress uses 10-year forecasts for budgeting purposes, which is currently 2010 through 2019. To better understand the long-term budget implications of the bill, we present spending estimates for both the 2010 through 2019 budget window and the 2020 through 2029 period.

Expertise Area: Health Reform

Using Electronic Health Data to Support Effectiveness Research and Medical Product Safety

February 2010

Lewin Contact: Cliff Goodman

A presentation at the Health IT Summit for Government Leaders conference on use of EHR to support CER and Medical Product Safety programs.

Expertise Area: Comparative Effectiveness Research

Health Reform and Employer Costs -- Presentation to Cleveland Health Action Council

January 2010

Lewin Contact: John Sheils


Expertise Area: Health Reform

Laboratory Medicine and Comparative Effectiveness Research

January 2010

Lewin Contact: Cliff Goodman

Comparative effectiveness research (CER) is reshaping the evaluation of health care technology in the United States, with implications for innovation, regulation, payment, access, quality, and costs. The interest in CER arises from a widely perceived shortfall in evidence to inform decisions by clinicians, patients, health care provider organizations, and payers. The evidence expectations inherent in CER offer distinct challenges to the laboratory sector, as well as opportunities for those that can demonstrate the value of laboratory tests in the CER paradigm. 

This report explains the rationale for CER, what CER is, and its significance for laboratory medicine. It describes the types of evidence generated by CER and how it compares with the evidence usually generated for regulatory purposes. The report summarizes current federal activities in CER that are relevant to laboratory medicine. Further, it describes implications of CER for the laboratory testing sector.

Client Area: Associations
Expertise Area: Comparative Effectiveness Research

Clarification Regarding The Lewin Group Analysis of House and Senate Bills

December 2009

Affordable Healthcare for America Act (H.R. 3962) as passed by the U.S. House of Representatives, and the Patient Protection and Affordable Care Act (H.R. 3590, being considered in the U.S. Senate)
Lewin Contact: John Sheils

The Lewin Group does not advocate for or against any legislation, and maintains editorial independence with respect to all work products.  This document provides further clarifications about the recent study.

Expertise Area: Health Reform

Appendices - Comparing the Cost and Coverage Impacts of the House and Senate Leadership Health Reform Bills

December 2009

Long Term Costs for Governments, Employers, Families and Providers
Lewin Contact: John Sheils

The appendices for the main report.

Expertise Area: Health Reform

Comparing the Cost and Coverage Impacts of the House and Senate Leadership Health Reform Bills

December 2009

Long Term Costs for Governments, Employers, Families and Providers
Lewin Contact: John Sheils

Prepared for: The Peter G. Peterson Foundation

The purpose of this analysis was to compare the effects of two major proposals to reform the U.S. health care system. These include the Senate Leadership “Patient Protection and Affordable Care Act” and the “Affordable Health Care for America Act” passed by the House of Representatives.

In this study we provide estimates of the program’s impact on coverage and spending for the federal government, state and local governments, private employers, consumers and providers. We estimated the impact of both bills on federal spending over a 20 year period from 2010 through 2029. The Congress uses 10-year forecasts for budgeting purposes, which is currently 2010 through 2019. To better understand the long-term budget implications of the bill, we present spending estimates for both the 2010 through 2019 budget window and the 2020 through 2029 period.

Expertise Area: Health Reform

Evaluation of New York’s HIV Special Needs Plan Program: Cost and Usage Impacts

November 2009

New York State Department of Health AIDS Institute
Lewin contact: Joel Menges

The Lewin Group, in collaboration with the New York State Department of Health AIDS Institute, conducted an evaluation of New York State’s Medicaid HIV Special Needs Plan program. The study focused on the following impact areas:  inpatient hospital costs and utilization, prescription drug costs and utilization, trends in overall medical costs, and the program’s effect on cost and HIV SNP enrollees’ service utilization compared to Medicaid spending had the HIV SNP initiative not been implemented.

Client Area: State and Local Governments
Expertise Area: Medicaid and CHIP

Key Findings - Senate Finance Health Reform Bill

November 2009

Lewin Group Analysis of Long Term Costs of The America’s Healthy Future Act of 2009
Lewin Contact: John Sheils

Expertise Area: Health Reform

Long-Term Cost of the America’s Healthy Future Act of 2009: As Passed by the Senate Finance Committee

October 2009

Prepared for The Peter G. Peterson Foundation
Lewin Contact: John Sheils

The Lewin Group released a study of the impact on the federal budget and deficit of the Senate Finance bill, America's Healthy Future Act of 2009 ("the Act").  The report was commission by the Peter G. Peterson Foundation, which also released its analysis and commentary on the Act, drawing upon the Lewin report.

Expertise Area: Health Reform

Comparative Effectiveness Research and Personalized Medicine: From Contradiction to Synergy

October 2009

Lewin Contact: Cliff Goodman

The Lewin Group Center for Comparative Effectiveness Research released a report prepared for the Personalized Medicine Coalition describing how comparative effectiveness research (CER) can be designed, conducted, and reported to better align with personalized medicine, achieving a synergy toward improved patient outcomes.  While CER has been oriented largely toward evaluating treatment effects across study populations, personalized medicine focuses on using individuals’ genomic information and other personal traits to inform decisions about their health care.  It is essential that these emerging initiatives evolve to complement, not contradict, each other. 

Expertise Area: Comparative Effectiveness Research

Can We Reduce Health Care Spending?

October 2009

Searching for Low-Hanging Fruit in the Garden of Health System Reform
Lewin Contact: Carol Simon

In this paper, we examine the recent literature documenting the major drivers of health care costs in
the U.S. and identify where new policies and initiatives could reduce costs without adversely affecting quality or access to medically necessary care.

Expertise Area: Health Reform

Reconciling the CBO and Lewin Estimates on the Public Plan

October 2009

American Affordable Health Choices Act of 2009
Lewin Contact: John Sheils

Updated October 22, 2009

Expertise Area: Health Reform

Colorado Works Evaluation 2009 Annual Report

October 2009

Colorado Department of Human Services
Lewin Contact: Sam Elkin

This annual report presents the findings from the Colorado Works Evaluation from activities conducted during State Fiscal Year 2009. In 2005, the Colorado Department of Human Services contracted with The Lewin Group and its partners, the University of Colorado’s Health Sciences Center, the Johns Hopkins University’s Institute for Policy Studies, and Capital Research Corporation, to perform an in-depth study of the state’s Temporary Assistance for Needy Families program. This report examines caseload trends, work participation, employment outcomes of program participants and leavers, and service delivery variation across Colorado counties. It reviews TANF trends and outcomes in light of the recession.

Client Area: State and Local Governments
Expertise Area: Income Security

The Value of Laboratory Screening and Diagnostic Tests for Prevention and Health Care Improvement

September 2009

American Clinical Laboratory Association; Advanced Medical Technology Association (AdvaMed)
Lewin contact: Clifford Goodman

The contributions of clinical laboratory screening and diagnostic tests to health care quality and outcomes are substantial. These contributions were described in an earlier report from The Lewin Group, The Value of Diagnostics Innovation, Adoption, and Diffusion in Health Care (2005). This report updates key elements of that study, providing a current overview of the important role of laboratory screening and diagnostic tests in our health care system, today’s means of assessing value, and four case studies documenting value of specific tests to patient care.

Client Area: Associations
Expertise Area: Evidence-Based Medicine / HTA

The Value of Laboratory Screening and Diagnostic Tests for Prevention and Health Care Improvement

September 2009

The paper is located here. The other link provides you a link to the web page for the conference and other materials.
Lewin Contact: Cliff Goodman


Client Area: Associations
Expertise Area: Comparative Effectiveness Research

Long-Term Cost of the American Affordable Health Choices Act of 2009; As Amended by the Energy and Commerce Committee In August 2009

September 2009

Peter G. Peterson Foundation Report
Lewin Contact: John Sheils

In this study for the Peter G. Peterson Foundation, we estimate the impact of The American Affordable Health Choices Act of 2009 (H.R. 3200) (Act) as amended by the Energy and Commerce (E&C) Committee in August of 2009.  We provide estimates of the program’s impact on coverage and spending for the federal government, state and local governments, private employers and consumers. To demonstrate the long-term impact of the Act, we provide estimates for a 20-year period from 2010 through 2029.

Expertise Area: Health Reform

Economic Analysis of Availability of Follow-on Protein Products

September 2009

DHHS, Office of the Assistant Secretary for Planning and Evaluation (ASPE)
Lewin contact: Clifford Goodman

Unlike most conventional drugs, biological products are usually large, complex molecules that are produced by living organisms. These commercially engineered biologics currently account for billions of dollars in health care spending. Starting early last century, Congress has regulated most biologics separately from small molecules under the Biologics Control Act, which was later incorporated into the Public Health Service (PHS) Act. Although some biologics are regulated under the Federal Food, Drug, and Cosmetic Act (FDCA) for historical reasons, and are, therefore, candidates for generic production through section 505(j), an Abbreviated New Drug Application (ANDA), or through 505(b)(2), using data from previously approved innovator biologics to make claims of safety and effectiveness, there is no abbreviated path for replica or closely similar follow-on products for biologics under the PHS Act. While this group of products is known by various names, this report uses the term “follow-on protein products” (FoPPs).

Due to the potential cost savings that FoPPs could provide in the US market, members of Congress have made various proposals for establishing a regulatory pathway for FoPPs. The purpose of this report is to provide an unbiased estimate of potential cost savings from the introduction of FoPPs under multiple scenarios for abbreviated regulatory pathways. Findings from this analysis may be useful in the context of ongoing policy deliberations. A better understanding of the potential impact of legislative provisions for the regulatory pathway on cost savings may inform policymakers as such a pathway is considered.

Client Area: Federal Government

Showing 26 item(s)

Contact Us
  703.269.5500
M–-F, 8:30–5:30 Eastern Time

  Email The Lewin Group

“It’s a pleasure to work with Lewin. They provide us with quality products and are very open to feedback. We have an excellent working relationship and are confident in their ability to provide exceptional service.”  FEDERAL AGENCY